Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier.

These results highlight functional differences in the integrity of the BBTB and tumor vessel phenotype between commonly utilized preclinical models of MB, with important implications for the preclinical evaluation of novel therapeutic agents for MB.